Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beraprost sodium for coronary microcirculation and ventricular remodeling in STEMI
NCT05043558Phase 2Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of beraprost in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Myocardial infarction characteristics at 3 years. Status: unknown.
02
Drugs
beraprost
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05043558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043558.